# Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients

> **NCT04538911** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** BCG-PPD

## Key facts

- **NCT ID:** NCT04538911
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-02
- **Primary completion:** 2023-05-18
- **Final completion:** 2025-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04538911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04538911, "Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04538911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*